Dicron

Quick links to important sections

Dicron

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicron

What is Dicron? (Enhanced E-E-A-T Overview)

The foundational identity of Dicron is established by its sole active component, Diflorasone Diacetate. It is a synthetic, high-potency agent used exclusively for external skin application and is available by prescription only (Rx only).

Property Description
Active ingredient Diflorasone Diacetate
Form Topical (Cream, Ointment, Lotion)
Pharmacological class Glucocorticoid (Corticosteroid subgroup)
Common purpose Alleviation of inflammatory and pruritic skin manifestations
Origin Synthetic (Fluorinated Steroid)

What Type of Medicine is Dicron?

Dicron is a synthetic topical corticosteroid containing the active pharmaceutical ingredient Diflorasone Diacetate. It is fundamentally classified as a Glucocorticoid, a powerful subgroup of the broader Corticosteroids family used in dermatology. As a fluorinated steroid, this medicine is entirely manufactured, confirming its synthetic origin. Diflorasone Diacetate is consistently ranked in the high-potency range when compared to other topical corticosteroids, a feature necessary for treating more severe or resistant inflammatory dermatoses. This potency is a key differentiator from the lower-strength agents commonly found in over-the-counter preparations.


Dicron's Composition and Physical Forms

The composition of Dicron is solely focused on the therapeutic action of Diflorasone Diacetate, establishing it as a single-ingredient product intended for topical administration only. The drug's mechanism is driven by its strong anti-inflammatory and vasoconstrictive properties. This steroid is used for its potent anti-inflammatory effects and action against skin inflammation, swelling, and itching. This means the core function is to suppress the skin's aggressive response to inflammation, a typical scenario being flare-ups of chronic dermatitis.

It is supplied in different topical dosage forms, including a cream, an ointment, and sometimes a liquid lotion. The active substance is combined with a specialized dermatological vehicle system or base. The selection of the specific form—such as the occlusive ointment base versus the lighter cream—is designed to optimize the delivery and absorption of the active ingredient for application across diverse skin areas and textures.

What side effects are possible with Dicron?

Possible side effects and safety information for Dicron

The safety profile of Dicron (Diflorasone Diacetate) is officially documented and primarily addresses two categories of adverse reactions: local dermatological events and potential systemic effects resulting from absorption of the high-potency agent. All factual statements align with government regulatory classifications.


Official Adverse Reaction Scope

Category Officially Documented Information
Common Local Reactions Burning sensation, itching (pruritus), irritation, and dryness at the site of application.
Uncommon Reactions Skin thinning (atrophy), development of stretch marks (striae), and hypertrichosis.
System-Organ Classes Primarily Skin and Subcutaneous Tissue Disorders. Risks extend to Endocrine Disorders (e.g., HPA axis suppression), Metabolism Disorders, and Eye Disorders (e.g., cataracts).

Serious Adverse Reactions and Safety Patterns

The most significant, though less frequent, safety concerns are related to the systemic absorption of the high-potency steroid, which regulatory bodies classify as potential serious adverse reactions:

  • Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Cushing's Syndrome are documented risks, particularly with extensive or prolonged use.
  • Pediatric patients are officially noted as being more susceptible to this systemic toxicity due to a higher skin surface area-to-body weight ratio. The risk of Intracranial Hypertension is also documented in this population.

The incidence of both local and systemic adverse reactions is officially stated to increase with long-term or extensive use and the application of occlusive dressings over the treated area. Safety constraints prohibit use in the presence of existing conditions like tuberculosis of the skin or viral/fungal skin infections, and the medicine is strictly not for ophthalmic use.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediately contact emergency services (911 or Poison Control) in all cases of suspected overdose.

An overdose of Dicron, like other medicines in its class, primarily affects the central nervous system. Symptoms are generally an extension of the known pharmacological effects, but more pronounced.

Overdose presentations typically range from mild to severe, and are described in regulatory documents as:

  • Mild to Moderate: Drowsiness, mental confusion, lethargy, dizziness, and impaired coordination (ataxia).
  • Severe: Severe drowsiness, hypotension (low blood pressure), depressed or stopped breathing (respiratory depression), and coma.

While an overdose of this medication taken alone is generally not life-threatening, the risk of severe outcome, including a fatal event, is substantially increased when the drug is combined with other central nervous system depressants, especially alcohol.

There is no specific agent to completely reverse the effects of an overdose. Treatment is supportive and symptomatic, focusing on the careful monitoring of vital signs (respiratory and cardiac function) and maintaining airway stability until the drug is cleared from the body. Because of the risk of severe respiratory depression, prompt professional medical attention is mandatory for all suspected overdose scenarios.

Therapeutic Uses of Dicron

What Dicron Treats: Main Uses and Benefits

Dicron (Diflorasone Diacetate) is commonly used in situations involving certain distressing symptoms and is relevant for easing the inflammatory and itching manifestations of skin conditions that respond to appropriate management. It is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load during periods of heightened disease activity.


This topical medication is generally used across conditions characterized by periods of heightened symptoms and episodic patterns. It is used across conditions presenting with acute episodes, including Psoriasis, Eczema, and various Dermatitis types. It may be applied in clinical settings marked by heightened patient distress and significant inflammatory manifestations. By helping to address symptom clusters such as pronounced itching (pruritus), aggressive redness (erythema), and swelling, the treatment provides support that helps ease the overall symptom burden.

“The treatment assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”

Therapeutic Focus: Pruritus Management

Dicron is commonly used to help manage symptoms that interfere with daily comfort, particularly the intense, persistent itching associated with acute flare-ups of chronic skin conditions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dicron (Diflorasone Diacetate) — Official Regulatory Information

The eligibility profile for Dicron is strictly defined by regulatory authorities and centers on absolute contraindications, age limitations, and specific condition restrictions.


Absolute Contraindications

Classification Population/Condition
Must Not Use Patients with a known history of hypersensitivity or allergy to Diflorasone Diacetate or any component of the preparation.

Age-Related Eligibility and Restrictions

  • Adult Patients: Approved for use in adults for labeled corticosteroid-responsive dermatoses.
  • Pediatric Patients: The safety and effectiveness have not been established in pediatric patients. Children are considered at greater risk of systemic effects than adults due to their body surface area ratio. Tight-fitting diapers should not be used if the medicine is applied to the diaper area, as this increases absorption risk.
  • Geriatric Patients: Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects.

Conditional Use and Site Restrictions

  • Specific Conditions: The medicine should not be used to treat rosacea or perioral dermatitis.
  • Body Site: Use is restricted; Dicron should not be used on the face, groin, or axillae (armpits).
  • Pregnancy: Classified as Category C; use is conditional and only permitted if the potential benefit justifies the potential risk to the fetus.
  • Lactation: Caution should be exercised when administered to a nursing woman, as it is unknown if the drug passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Dicron (Diflorasone Diacetate), a high-potency topical corticosteroid, is predominantly defined by the risk of systemic absorption and subsequent pharmacodynamic effects, rather than specific drug-drug metabolic interactions.

Pharmacodynamic and Exposure-Altering Interactions

Interaction Type Documented Interaction Statement
Pharmacodynamic Risk Co-administration with other corticosteroid-containing preparations may result in additive systemic effects, increasing the overall potential for systemic toxicity, such as HPA axis suppression.
Exposure Modification The use of occlusive dressings (covering the treated area) is documented to substantially increase the percutaneous absorption of the medicine, significantly raising the potential for systemic exposure.

Population-Specific Caution

Pediatric patients are officially noted to be more susceptible to systemic toxicity from the medicine, including HPA axis suppression and Cushing's syndrome manifestations. This increased susceptibility is an important population-specific factor affecting the risk of systemic interaction due to their higher ratio of skin surface area to body mass. Formal regulatory documents do not list specific drug-drug, food, alcohol, or herbal product interactions, nor are mandatory timing or separation rules documented for this topical medication.

Mechanism of Action

How Dicron Works

The drug's mechanism of action is defined by two distinct mechanistic domains that influence gene-level signaling and mediator production within pathways associated with inflammation.


Action via Intracellular Genomic Signal Modulation

This domain covers the drug’s primary action: agonism of the Glucocorticoid Receptor (GR) inside the cell. By binding to the GR, Dicron alters gene expression through both transactivation (upregulating anti-inflammatory genes) and transrepression (downregulating pro-inflammatory factors like NF-kappaB), initiating regulation of immune signaling activity. This mechanism is central to modulating the cellular mechanisms of the inflammatory and immune response.


Interruption of the Arachidonic Acid Cascade

This domain addresses the drug's effect on enzyme systems. The genomic changes triggered by the receptor activation lead to the production of Lipocortin (Annexin A1), which is an endogenous inhibitor of the Phospholipase A2 (PLA2) enzyme. Blocking PLA2 prevents the cell from synthesizing biochemical mediators like prostaglandins and leukotrienes, leading to the physiological inhibition of signals that mediate localized edema and nociceptive pathways.


Localized Vascular Tone Adjustment

This domain involves the drug's rapid, localized influence over dermal blood vessels. It induces vasoconstriction, or the narrowing of capillaries, which reduces blood flow and vascular permeability at the site of application. This rapid non-genomic action contributes to modulating the downstream physiological manifestations, such as localized redness (erythema) and the leakage of fluid (edema).

Dosage and Administration Information

How Dicron is Used

Dicron (Diflorasone Diacetate) is a high-potency agent exclusively administered via the topical route for external application to the skin. Usage protocols specify that the medication must be applied as a thin film to the affected area, with the frequency of application depending on the specific dosage form used.

Dosing Frequencies and Forms

Dosage Form (0.05% Strength) Frequency of Application
Cream Twice daily
Ointment One to three times daily

Administration Protocol

The course of therapy for Dicron is generally short-term and is governed by the principle of discontinuation when control is achieved, rather than by a fixed duration. The medication is intended strictly for external use and contact with the eyes should be avoided.

The treated skin area should not be covered with occlusive dressings such as bandages or tight wraps, unless such use is specifically directed by a healthcare provider. Furthermore, the product should generally not be used on sensitive areas including the face, groin, or axillae. For pediatric patients, caregivers are advised against using tight-fitting diapers or plastic pants over treated areas, as these act as occlusive coverings and may affect absorption.

These guidelines define the standardized method for proper application, ensuring the medicine is used according to its intended scope.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dicron (Diflorasone Diacetate)

This section summarizes the official clinical research and regulatory evaluations conducted for Dicron, focusing on the types of studies that exist, the populations examined, and the primary outcomes measured in trials. This overview is purely descriptive and does not offer clinical advice or interpret results for individual patient use.


Evidence for use in Psoriasis

The core evidence for Psoriasis comes from short-term randomized controlled trials (RCTs) and comparative studies. Research examined outcomes related to physical discomfort and clinical signs, such as erythema (redness), scaling, and induration (thickness), in adult populations with moderate to severe disease. Studies monitored changes measured during the study period, focusing on a defined time interval. Trial reports documented the observed changes in clinical signs, such as measurements related to redness and thickness, in patients using the product when compared to using an inactive cream or other steroid applications. The findings describe patterns observed in the studies related to changes in Psoriasis symptoms during the brief treatment periods.

Evidence for use in Eczematous Dermatoses

For Eczematous Dermatoses, including Atopic Dermatitis, Dicron was evaluated in controlled trials. These studies were used in research exploring how symptoms change over time, focusing on conditions characterized by fluctuating or episodic manifestations. The research examined outcomes linked to inflammatory or irritative states, such as pruritus (itching) and erythema. Trial reports recorded measurements of symptoms over brief treatment durations, with many trials concluding assessments within a two-to-three-week window. Data collected in specialized regulatory assays were also reported to support the medicine's classification within the high-potency category of topical steroids.

Duration of Study and What Remains Uncertain

The clinical research primarily involves short-term follow-up durations (typically 2 to 4 weeks) across the main efficacy trials. As a result, long-term effects are not fully established. Evidence contributes to understanding symptom patterns during the initial use, but there is limited information for long-term outcomes or the durability of the observed response. Furthermore, the safety and effectiveness have not been established in pediatric patients, according to official regulatory information, indicating that this group was not observed in sufficient controlled research. The results apply only to the populations studied, which were primarily adults with Psoriasis and Eczema.

Frequently Asked Questions (FAQ)

Common questions about Dicron (FAQ)

Q: Is Dicron an opioid or a narcotic painkiller?

A: No, Dicron (Diflorasone Diacetate) is not an opioid or a narcotic painkiller. Official product information classifies it as a high-potency topical corticosteroid (glucocorticoid), which means it is a powerful anti-inflammatory medicine applied only to the skin.

Q: How does Dicron work to relieve pain and swelling in the body?

A: Dicron works due to its anti-inflammatory and anti-pruritic (anti-itch) actions. It also causes vasoconstriction, which is the narrowing of small blood vessels at the site of application. These combined actions are designed to reduce the localized redness, swelling, and discomfort associated with skin inflammation.

Q: What kind of conditions, besides arthritis, is Dicron typically prescribed for?

A: According to official regulatory documents, Dicron is indicated for the relief of inflammatory and itchy manifestations of corticosteroid-responsive dermatoses. This typically includes conditions such as psoriasis and atopic dermatitis (a common form of eczema).

Q: Is Dicron considered a long-term or short-term pain relief medication?

A: Dicron is generally intended for short-term use. Official usage instructions state that the course of therapy should be stopped once the skin condition is controlled, rather than continuing for a fixed duration. Long-term or extensive use can increase the potential risk of systemic side effects.

Q: Are there any serious, but less common, side effects I should know about before taking Dicron?

A: Yes, official warnings address potential serious systemic effects related to the high-potency nature of the drug. These less common reactions include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. There is also a risk of eye disorders such as cataracts or glaucoma with extensive use.

Q: Is it normal to feel dizzy or drowsy after taking Dicron?

A: Dizziness is an adverse reaction that has been noted in safety data, but drowsiness is not typically listed. If you experience dizziness or other unusual systemic symptoms, you can discuss them with a healthcare provider.

Q: Can Dicron be taken at the same time as Tylenol (paracetamol/acetaminophen)?

A: There are no specific drug-drug, food, or alcohol interactions formally documented for this topical product. However, always discuss the use of any other skin products on the same area with a healthcare professional.

Q: Is it safe to drink alcohol in moderation while using Dicron?

A: The official product information does not list any specific interactions between Dicron (applied topically) and alcohol.

Q: Can Dicron be taken with common acid reflux or heartburn medications?

A: Official documentation does not list specific drug-drug or food interactions with acid reflux or heartburn medications for this topical product.

Q: Does Dicron affect blood pressure, and should I monitor it while using the drug?

A: Manifestations of the drug's systemic absorption, such as HPA axis suppression, may potentially lead to symptoms like low blood pressure (hypotension) or rapid, sudden weight gain. A healthcare provider is the best source for advice regarding monitoring, especially if you have pre-existing conditions.

Q: Can Dicron cause fluid retention or swelling in the ankles and feet?

A: Sudden weight gain has been noted as a potential systemic effect of topical corticosteroids. While localized swelling is not commonly listed, sudden weight changes should be discussed with a healthcare provider.

Q: How does Dicron differ from combination products like Dicron MR or Dicron SP?

A: Dicron (Diflorasone Diacetate) is officially defined as a single-ingredient product intended solely for topical application to the skin. The official product label does not contain information on combination products such as Dicron MR or Dicron SP.

Q: Can Dicron affect fertility or planning for pregnancy?

A: Dicron is classified as Pregnancy Category C, meaning its use during pregnancy is conditional. It is only permitted if the potential benefit justifies the potential risk. Furthermore, caution should be exercised if administered to a nursing woman, as it is unknown if the drug passes into breast milk.

Q: How does Dicron affect the body's inflammatory process?

A: Dicron affects the inflammatory process primarily by reducing the formation of chemical mediators that cause inflammation and itching. This action is supported by its ability to narrow blood vessels at the site of application, which helps reduce localized redness and swelling.

Q: Does the risk of serious side effects increase with higher doses of Dicron?

A: Official warnings state that the incidence of both local and systemic adverse reactions increases with long-term or extensive use of the medicine. The risk is also increased if the treated area is covered with occlusive dressings.

Q: Is it safe to drive or operate machinery while taking Dicron, especially the first time?

A: Adverse reactions such as dizziness and blurred vision have been noted in safety data. If you experience effects that may impair judgment or motor skills, it is important to consider their impact before driving or operating machinery.

Q: What happens if I miss a dose of Dicron?

A: Product labeling provides guidance on what to do if an application is missed. Generally, if an application is missed, it should be used as soon as it is remembered. If it is almost time for your next scheduled dose, skip the missed dose and return to your regular application schedule. Double or extra doses should not be used.

Q: Is there a risk of heart-related side effects, like heart attack or stroke, with Dicron?

A: While heart attack or stroke are not explicitly listed as common side effects, the label includes rare, serious systemic effects that can affect the body's systems, such as fast, irregular, or pounding heartbeats (palpitations).

Q: Can Dicron cause increased sensitivity to sunlight?

A: Skin photosensitivity, which is an increased sensitivity to sunlight, has been listed as a rare side effect in safety monitoring data for this topical drug class.

Q: What are the signs of a potential allergic reaction to Dicron?

A: Signs of a serious allergic reaction may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Should you experience any of these symptoms, immediate medical attention is required.

Q: What is the recommended storage temperature for Dicron tablets?

A: Dicron, which is a topical medicine (not a tablet), should be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be kept from freezing, excessive heat, moisture, and light.

How should Dicron be stored and disposed of?

Dicron (Diflorasone Diacetate) must be stored and handled according to the requirements specified in the official regulatory labeling.

Official Storage Conditions

Requirement Statement
Temperature Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F).
Environmental Protection Must be kept from freezing and stored away from excess heat, moisture, and direct light.
Container Keep the medicine in its original container and ensure the container is kept tightly closed when not in use.
Child Safety The product must be kept out of the sight and reach of children.

Official Disposal Instructions

Outdated or no longer needed medicine should not be kept. Patients are instructed to ask a healthcare professional how to dispose of any unused product. General guidelines recommend discarding the product using an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash, avoiding environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dicron found in:

A-Z Index: